Kilroy Realty Corporation with ticker code (KRC) now have 13 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 48 and 32 and has a mean target at $39.54. Now with the previous closing price of $27.56 this would imply there is now a potential upside of 43.5%. The 50 day moving average now sits at $31.66 and the 200 day moving average is $40.85. The market capitalization for the company is $3,260m. You can visit the company’s website by visiting: https://www.kilroyrealty.com
The potential market cap would be $4,676m based on the market consensus.
Kilroy Realty Corporation (NYSE: KRC, the company, Kilroy) is a leading U.S. landlord and developer, with operations in San Diego, Greater Los Angeles, the San Francisco Bay Area, the Pacific Northwest and Austin, Texas. The company has earned global recognition for sustainability, building operations, innovation and design. As pioneers and innovators in the creation of a more sustainable real estate industry, the company’s approach to modern business environments helps drive creativity and productivity for some of the world’s leading technology, entertainment, life science and business services companies. The company is a publicly traded real estate investment trust (REIT) and member of the S&P MidCap 400 Index with more than seven decades of experience developing, acquiring and managing office, life science and mixed-use projects. As of December 31, 2022, Kilroy’s stabilized portfolio totaled approximately 16.2 million square feet of primarily office and life science space that was 91.6% occupied and 92.9% leased. The company also had more than 1,000 residential units in Hollywood and San Diego, which had a quarterly average occupancy of 93.3%. In addition, the company had two in-process life science redevelopment projects with total estimated redevelopment costs of $80.0 million, totaling approximately 100,000 square feet, and three in-process development projects with an estimated total investment of $1.7 billion, totaling approximately 1.7 million square feet of office and life science space. The in-process development and redevelopment office and life science space is 36% leased.
The company has a dividend yield of 7.84% with the ex dividend date set at 30-3-2023 (DMY).
Other points of data to note are a P/E ratio of 13.76, revenue per share of 9.62 and a 1.94% return on assets.
